updated 2/7/2011 9:17:04 AM ET 2011-02-07T14:17:04

SCHOFIELD, Wis., Feb. 7, 2011 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc. (OTCQB:PMBS) announced today that it has entered into an agreement with Double Pump, Inc. designed to enhance marketing efforts and product awareness surrounding the national retail launch of the Company's flagship LipiGesic™ M migraine product along with future PuraMed product offerings.

Founded in 1989, Double Pump, Inc. has a long history in product marketing and brand awareness development. Based in Southern California, Double Pump has long established relationships in the world of sports and corporate America and has assisted numerous companies to further their product launches through their consulting efforts.

Double Pump, Inc. clients such as Adidas, EA Sports, Nestle, Inc. and Powerade® have engaged Double Pump, Inc. to increase marketing efforts in the youth sports demographic and other areas.

"We have retained Double Pump, Inc. to assist us in our marketing campaign for LipiGesic™ M, which will include a search for a high-profile spokesperson for the product as well as introduction to various sales channels," said PuraMed BioScience CEO Russell Mitchell. "Double Pump, Inc. will also provide strategic advice with regards to several additional products that are currently under development. We believe Double Pump's experience with international brands, as well as their relationships with highly recognizable celebrities and athletes, makes them an excellent choice as a partner in launching LipiGesic™ M on the national level and building awareness of the product to the level of becoming a household name."

As previously announced in a press release on July 6, 2010, a clinical study of LipiGesic™ M has been completed. On Jan. 3, 2011, PuraMed also announced that the manuscript of the clinical study of LipiGesic™ M had been completed and submitted to a top-ranked medical journal for peer review. The Company now looks forward to potential publication of the results, which would generate awareness of the product's efficacy and explain how it should be properly used and even new labeling opportunities. In addition, publication of these results from the clinical study combined with intensified marketing efforts could likely also increase product visibility to both the medical community and the general public.

In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of the manuscript or any of the results of this study. The clinical study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks.

About PuraMed BioScience, Inc.:

PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches, the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for common tension headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com , join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed .

Forward Looking Statements:

This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

CONTACT: Russell Mitchell, Chairman and CEO
         PuraMed BioScience, Inc.
         715-359-6373
         rmitchell@PuraMedBioScience.com
         Website: www.PuraMedBioScience.com
         
         Investor Relations:
         Investor Awareness, Inc.
         Tony Schor or James Foy, 847-945-2222
         Website: www.investorawareness.com
         
         Media Contact:
         North Shore Public Relations, Inc.
         Renae Placinski, 847-945-4505
         Renae@northshorepr.com -- Website: www.northshorepr.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.73%
$30K home equity loan FICO 5.26%
$75K home equity loan FICO 4.70%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.42%
Cash Back Cards 17.94%
17.94%
Rewards Cards 17.14%
17.14%
Source: Bankrate.com